Free Trial
→ Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ADIL

Adial Pharmaceuticals 11/14/2023 Earnings Report

Adial Pharmaceuticals logo
$0.35 0.00 (-0.74%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.35 +0.00 (+1.14%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Adial Pharmaceuticals EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.14
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Adial Pharmaceuticals' next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
September 5, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30312437
Adial granted a 180 calendar day extension by Nasdaq to regain compliance
September 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/adial-granted-a-180-calendar-day-extension-by-nasdaq-to-regain-compliance/ar-AA1LNIk0
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
September 13 at 2:00 AM  |  Banyan Hill Publishing (Ad)
Adial Pharmaceuticals Receives 180-Day Extension to Regain Nasdaq Compliance with Minimum Bid Price Requirement
September 3, 2025  |  quiverquant.comQ
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
September 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/03/3143607/26135/en/adial-pharmaceuticals-granted-a-180-calendar-day-extension-by-nasdaq-to-regain-compliance-with-the-minimum-bid-price-rule.html
Zelira Therapeutics (OTCMKTS:ZLDAF) vs. Adial Pharmaceuticals (NASDAQ:ADIL) Head to Head Review
September 3, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30309418
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts.

Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles